US Merger & Acquisition SEC Filings — April 07, 2026

07-04-2026

On April 6, 2026, Aquaron Acquisition Corp., a blank check company, issued an unsecured promissory note for $16,198.05 to HUTURE Ltd. in exchange for depositing the amount into its trust account to extend the deadline for completing a business combination. The interest-free note matures upon closing of the business combination and is convertible into common stock units (one share plus one-fifth share right) at $10.00 per unit.

07-04-2026

Athena Technology Acquisition Corp. II deposited $497.74 into its trust account on April 6, 2026, to extend the deadline for consummating its initial business combination by one month, from April 14, 2026, to May 14, 2026. This represents the eighth of up to nine potential monthly extensions permitted under the company's Amended and Restated Certificate of Incorporation.

• ·Company is classified under Hazardous Waste Management [SIC 4955], incorporated in Delaware with EIN 87-2447308.
• ·Emerging growth company status confirmed.

07-04-2026

CVD Equipment Corporation completed the sale of its Stainless Design Concepts (SDC) division for a purchase price of approximately $16.9 million in cash, subject to customary adjustments. Net cash proceeds after transaction expenses and taxes are approximately $15.0 million, with $900,000 held in escrow for potential post-closing obligations. The company will retain its Saugerties, New York facility and lease it to the buyer for an initial term of two years, using proceeds to enhance financial flexibility and support strategic initiatives.

• ·Announcement date: April 2, 2026
• ·Filing date: April 07, 2026
• ·Saugerties, New York facility retained and leased to buyer for initial two-year term

07-04-2026

On April 3, 2026, Ginkgo Bioworks Holdings, Inc. completed the contribution of its Biosecurity segment (Ginkgo Biosecurity, LLC) to Tower Biosecurity, Inc. (also known as Perimeter Systems, Inc.) in exchange for approximately 20% of the Purchaser's equity on a fully diluted basis, representing a strategic shift with Biosecurity results to be reported as discontinued operations starting in the Q1 2026 10-Q. Pro forma financials for 2025 show total revenue declining 22% to $132.7M (from $170.2M historical) after removing $37.4M Biosecurity revenue, but net loss improved to $287.8M (from $312.8M) due to elimination of associated costs. While losses narrowed YoY in pro forma results (2025 $287.8M vs. 2024 $507.6M), core Cell Engineering revenue fell 24% from 2024 pro forma levels, highlighting ongoing profitability challenges.

• ·Pro forma net loss per share for 2025: $(6.00) vs historical $(5.64)
• ·Biosecurity service revenue removed: $37.4M in 2025, $53.1M in 2024, $78.975M service + $28.9M product in 2023
• ·Pro forma investments increase by $12.3M from equity method accounting of 20% stake
• ·Historical goodwill impairment $47.9M and lease impairment $96.2M remain in pro forma results

07-04-2026

Real Asset Acquisition Corp. (RAAQ) and IQM announced via joint press release the confidential submission of a draft registration statement on Form F-4 to the SEC on April 7, 2026, advancing their previously announced business combination agreement dated February 22, 2026, which aims to take IQM public. The filing includes a preliminary proxy statement/prospectus, with definitive materials to be mailed to RAAQ shareholders ahead of an extraordinary general meeting. No financial metrics or performance data were disclosed, though extensive risks including redemption risks and regulatory approvals were highlighted.

• ·Business Combination Agreement entered on February 22, 2026.
• ·Press Release filed as Exhibit 99.1.
• ·RAAQ securities: RAAQU (Units), RAAQ (Class A ordinary shares), RAAQW (Redeemable warrants exercisable at $11.50 per share).
• ·Emerging growth company status confirmed.

07-04-2026

Alchemy Investments Acquisition Corp 1 (Alchemy) and Cartiga, LLC (Cartiga) have prepared an Investor Presentation dated April 2026 for use in investor presentations regarding a potential business combination under a Business Combination Agreement (BCA). The presentation is attached as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. Alchemy Acquisition Holdings, Inc. intends to file a Registration Statement on Form S-4, including a proxy statement/prospectus, with the SEC.

• ·Securities registered on Nasdaq Stock Market, LLC.
• ·Alchemy is an emerging growth company.
• ·Prospectus filed with SEC on May 5, 2023 (dated May 4, 2023, File No. 333-268659).

07-04-2026

Supernus Pharmaceuticals, Inc. entered into an Asset Purchase Agreement effective April 1, 2026, with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC to acquire certain assets related to the Compound (NV-5138 or SPN-820), following exercise of an option under a prior Development Agreement (April 21, 2020) and a Binding MOU (May 5, 2025). The acquisition targets a late-stage psychiatry pipeline asset to complement Supernus's CNS neurology portfolio. No purchase price or financial terms are disclosed in the provided filing excerpt.

• ·Filing Type: 8-K (Items 1.01, 2.01, 9.01)
• ·Filing Date: April 07, 2026
• ·Buyer described as public CNS specialty pharmaceutical company with neurology assets and late-stage psychiatry pipeline

07-04-2026

Haymaker Acquisition Corp. 4, a Cayman Islands exempted company, entered into a Non-Redemption Agreement dated April 1, 2026, with an undersigned shareholder (Holder) regarding its pending Business Combination with Concrete Partners Holding, LLC, originally agreed on October 9, 2025. The Holder, who had elected to redeem 250,000 Public Shares, agreed to reverse the redemption, waive further redemption rights on these shares, refrain from transferring them until closing, and vote them in favor of the Business Combination. In exchange, the Company will pay the Holder post-closing an amount equal to (actual redemption price per share minus $10.75) multiplied by 250,000 shares.

• ·Agreement filed as Exhibit 99.1 in 8-K on April 07, 2026 (Items 1.01, 5.07, 9.01)
• ·Public Shares have par value $0.0001 per share
• ·Holder may own additional 'Other Shares' not subject to this agreement and eligible for redemption
• ·Payment conditioned on Redemption Reversal evidence, holding shares through Closing Date, and compliance with voting/no-transfer covenants

07-04-2026

Runway Growth Finance Corp. completed its acquisition of SWK Holdings Corporation on April 6, 2026, for a final purchase price of $249.0 million ($75.5 million in shares at $11.93 NAV per share and $173.5 million in cash), plus an additional $9.0 million cash contribution from its investment adviser, expanding total assets to $1.2 billion pro forma and increasing healthcare/life sciences exposure to 32% from 14% as of December 31, 2025. In Q1 2026, the company funded $17.6 million across four investments and received $19.0 million in liquidity events, including a full $15.0 million repayment from Moximed. The acquisition is expected to be accretive to net investment income, with David Spreng returning as Chief Investment Officer.

• ·SWK NAV per share at closing: $11.93
• ·SWK final NAV struck 48 hours prior to April 6, 2026 closing (excluding Sundays/holidays), reflective of retained earnings from June 30, 2025
• ·Investment Committee: David Spreng, Tom Raterman, Patrick Schafer

07-04-2026

On March 31, 2026, SC II Acquisition Corp., a blank check company (SPAC), entered into a non-binding letter of intent with an unnamed payments technology company outlining a potential business combination for the acquisition of 100% of the target's outstanding equity and equity equivalents. The LOI includes limited binding provisions such as exclusivity and confidentiality but imposes no obligation to consummate the transaction. The filing cautions on risks including failure to execute definitive agreements, regulatory approvals, high redemptions, and transaction costs.

• ·Filing Date: April 7, 2026
• ·Event Date: March 31, 2026
• ·Securities: Units (SCIIU), Class A ordinary shares par value $0.0001 (SCII), Rights (SCIIR) listed on Nasdaq Stock Market LLC
• ·Company CIK: 0002076739, EIN: 98-1876716, Incorporated in Cayman Islands
• ·Target: unnamed payments technology company

07-04-2026

Hologic, Inc. completed its acquisition by funds managed by Blackstone and TPG, valued at up to $79 per share ($76 cash plus a non-tradable CVR for up to $3 in two $1.50 payments contingent on Breast Health revenue milestones in FY2026 and FY2027), transitioning to a private company with delisting from Nasdaq. José (Joe) E. Almeida, formerly CEO of Baxter International, was appointed Chief Executive Officer effective immediately, succeeding Stephen MacMillan. The deal includes minority investments from a subsidiary of Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC; no operational declines reported, though forward-looking risks include potential CVR shortfalls and business disruptions.

• ·Transaction announced October 21, 2025; stockholder approval February 5, 2026; completion April 7, 2026.
• ·Hologic common stock ceased trading and delisted from Nasdaq Stock Market.
• ·CVR payable in whole or part based on global revenue goals for Breast Health in fiscal years 2026 and 2027.

07-04-2026

QNB Corp. successfully completed its acquisition of Victory Bancorp, Inc., the holding company for The Victory Bank, on April 1, 2026, following all required regulatory and shareholder approvals. Joseph W. Major and Kevin L. Johnson joined QNB Bank's Board of Directors, and Victory Bank will operate as a division during an interim period until systems conversion over June 19-21, 2026, after which customers will access 14 full-service QNB Bank offices. The transaction strengthens QNB's franchise in Bucks, Lehigh, and Montgomery counties with no reported disruptions to customer service.

• ·Acquisition closed April 1, 2026; filing dated April 7, 2026.
• ·Interim operating period: April to mid-June 2026.
• ·Systems conversion: weekend of June 19-21, 2026; branches reopen June 22, 2026.
• ·Advisors: Performance Trust Capital Partners, LLC (QNB financial advisor); Stevens & Lee (QNB legal); Wolf & Company P.C. (Victory financial advisor); Kilpatrick Townsend & Stockton LLP (Victory legal).

07-04-2026

TCW Direct Lending VIII LLC completed an Exchange Offer on April 1, 2026, enabling unitholders to exchange Units for equivalent units in its wholly-owned subsidiary TCW Specialty Lending LLC (Perpetual Fund), resulting in the transfer of approximately 70% of assets, liabilities, and operations. Pro forma financials as of December 31, 2025, show total assets reduced to $887,530 thousand from $1,267,900 thousand (30% decline) and net investment income for the year decreased to $30,039 thousand from $100,129 thousand (70% decline), while net asset value per unit remained stable at $94.43. This restructuring provides unitholders perpetual-life investment optionality but significantly scales down the Company's size.

• ·Exchange Offer filed January 14, 2026, amended February 20, 2026 and March 8, 2026.
• ·Net Asset Value Per Unit stable at $94.43 (accrual base) pre and post pro forma.
• ·Term loan reduced pro forma to $227,106 thousand from $324,437 thousand.
• ·Pro forma adjustments reflect transfer as if occurred January 1, 2025.

07-04-2026

Northwest Biotherapeutics, Inc. completed the acquisition of Advent BioServices Ltd., a UK-based CDMO providing services for its DCVax platform, from Toucan Holdings LLC on October 24, 2025, for a purchase price of approximately $1.9 million plus payment of $8.3 million in outstanding accounts payable. The Company received back 12 million common shares and 5.5 million stock options previously issued to Advent, which were retired or cancelled. The transaction is a related party deal as CEO Linda Powers controls the seller, though it was approved per company policies and includes an SEC waiver for certain financial disclosures.

• ·Acquisition agreement dated August 27, 2025.
• ·Consideration payable in installments over two years, beginning 3 months after October 24, 2025 closing, with potential acceleration after DCVax-L regulatory approval.
• ·SEC waiver obtained under Rule 3-13 from requirements of Rule 3-05 and Article 11 of Regulation S-X for Advent financial statements and pro forma information.

07-04-2026

TCW Specialty Lending LLC completed an exchange offer on April 1, 2026, accepting 6,435,400 Fund VIII Units (50.49% of outstanding) for equivalent Company Units, with pro rata transfer of Fund VIII's assets and liabilities. The Company entered into amended governance, advisory, administration, and licensing agreements, while its subsidiary TCW SL Financing LLC established a $625M senior secured revolving credit facility (5-year term, SOFR + 2.10%), borrowing $262.4M to settle prior Fund VIII debt. No declines or underperformance noted in the filing.

• ·Exchange Offer documents dated January 14, 2026, amended February 20, 2026, March 9, 2026, and March 24, 2026.
• ·Credit Facility secured by portfolio investments and cash, with customary covenants, borrowing base, and events of default.
• ·Company Units issued in reliance on Rule 506(b) exemption under Section 4(a)(2) of the Securities Act.